In vivo and in vitro examination of stability of primary hyperoxaluria-associated human alanine:glyoxylate aminotransferase.
Primary hyperoxaluria type I is a severe kidney stone disease caused by mutations in the protein alanine:glyoxylate aminotransferase (AGT). Many patients have mutations in AGT that are not deleterious alone but act synergistically with a common minor allele polymorphic variant to impair protein folding, dimerization, or localization. Although studies suggest that the minor allele variant itself is destabilized, no direct stability studies have been carried out. In this report, we analyze AGT function and stability using three approaches. First, we describe a yeast complementation growth assay for AGT, in which we show that human AGT can substitute for function of yeast Agx1 and that mutations associated with disease in humans show reduced growth in yeast. The reduced growth of minor allele mutants reflects reduced protein levels, indicating that these proteins are less stable than wild-type AGT in yeast. We further examine stability of AGT alleles in vitro using two direct methods, a mass spectrometry-based technique (stability of unpurified proteins from rates of H/D exchange) and differential scanning fluorimetry. We also examine the effect of known ligands pyridoxal 5'-phosphate and aminooxyacetic acid on stability. Our work establishes that the minor allele is destabilized and that pyridoxal 5'-phosphate and aminooxyacetic acid binding significantly stabilizes both alleles. To our knowledge, this is the first work that directly measures relative stabilities of AGT variants and ligand complexes. Because previous studies suggest that stabilizing compounds (i.e. pharmacological chaperones) may be effective for treatment of primary hyperoxaluria, we propose that the methods described here can be used in high throughput screens for compounds that stabilize AGT mutants.
Hopper
Erin D
ED
Department of Biology and Chemistry, Duke University, Durham, North Carolina 27708, USA.
Pittman
Adrianne M C
AM
Fitzgerald
Michael C
MC
Tucker
Chandra L
CL
D000483:Alleles; D004795:Enzyme Stability / Q000187:drug effects / Q000235:genetics; D005816:Genetic Complementation Test / Q000379:methods; D006801:Humans; D006960:Hyperoxaluria, Primary / Q000201:enzymology* / Q000235:genetics; D008024:Ligands; D009154:Mutation; D010072:Oxamic Acid / Q000494:pharmacology; D011110:Polymorphism, Genetic; D011485:Protein Binding / Q000187:drug effects / Q000235:genetics; D011732:Pyridoxal Phosphate / Q000494:pharmacology; D012441:Saccharomyces cerevisiae / Q000201:enzymology / Q000235:genetics; D000637:Transaminases / Q000235:genetics / Q000378:metabolism*; D014803:Vitamin B Complex / Q000494:pharmacology
D008024:Ligands; D014803:Vitamin B Complex; D011732:Pyridoxal Phosphate; D000637:Transaminases; C019635:Alanine-glyoxylate transaminase; D010072:Oxamic Acid
Nat Med. 1999 Jan;5(1):112-5
9883849
Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):892-7
15642944
Am J Nephrol. 2005 Mar-Apr;25(2):183-8
15849466
J Biol Chem. 2000 Nov 17;275(46):36415-22
10960483
Biochim Biophys Acta. 2003 Apr 11;1647(1-2):315-20
12686151
Arch Biochem Biophys. 1998 Jan 1;349(1):175-82
9439596
Biochemistry. 2004 Aug 31;43(34):10896-905
15323550
Trends Pharmacol Sci. 2003 Jul;24(7):355-60
12871668
J Mol Biol. 2003 Aug 15;331(3):643-52
12899834
Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):15835-40
17035505
Biochim Biophys Acta. 2006 Dec;1763(12):1776-84
17027096
Ann Clin Biochem. 1997 Jul;34 ( Pt 4):400-4
9247673
Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7277-82
12777626
Nature. 2003 Oct 16;425(6959):686-91
14562095
Biochemistry. 2003 May 6;42(17):4962-70
12718538
Antimicrob Agents Chemother. 2007 Dec;51(12):4420-6
17908943
Hum Mol Genet. 2006 Sep 15;15(18):2743-51
16893904
J Biol Chem. 1980 May 10;255(9):4381-5
6989838
Eur J Cell Biol. 1994 Aug;64(2):295-313
7813517
Biochem J. 2003 Aug 15;374(Pt 1):79-87
12737622
Biochemistry. 1985 Jan 15;24(2):339-45
3884040
J Clin Invest. 2000 Apr;105(7):887-95
10749568
Protein Pept Lett. 2008;15(2):153-9
18289107
Yeast. 2004 Jan 15;21(1):63-73
14745783
Biochem Biophys Res Commun. 1991 May 15;176(3):1093-9
2039493
J Biol Chem. 2003 May 23;278(21):18990-6
12649274
Anal Biochem. 2001 May 1;292(1):40-50
11319816
Nat Protoc. 2007;2(9):2212-21
17853878
Biochemistry. 1997 Nov 25;36(47):14345-52
9398152
J Am Chem Soc. 2002 Sep 4;124(35):10256-7
12197709
J Cell Biol. 1990 Dec;111(6 Pt 1):2341-51
1703535
J Cell Sci. 1990 Dec;97 ( Pt 4):669-78
2127597
Am J Nephrol. 2005 May-Jun;25(3):303-10
15961951
Biochim Biophys Acta. 1998 Apr 23;1384(1):141-52
9602099
Anal Biochem. 2004 Apr 15;327(2):176-83
15051534
J Biol Chem. 1999 Jul 16;274(29):20587-96
10400689
J Biol Chem. 1995 Aug 18;270(33):19294-9
7642604
Protein Sci. 2002 Apr;11(4):841-51
11910027
Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15113-8
11752457
Methods Enzymol. 1972;26:43-50
4680720
Protein Expr Purif. 2005 May;41(1):18-26
15802217
J Comb Chem. 2004 Mar-Apr;6(2):262-9
15002975
J Biol Chem. 2000 Dec 22;275(51):40244-51
10995767
Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8296-301
10890887
Mol Genet Metab. 2006 Dec;89(4):349-59
16971151
J Biomol Screen. 2001 Dec;6(6):429-40
11788061
Biochem J. 1993 Oct 15;295 ( Pt 2):493-500
8240248
Clin Chem. 2007 Jul;53(7):1216-21
17495019
Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10900-4
1961759
FASEB J. 2005 Jan;19(1):12-8
15629890
Anal Biochem. 2004 Sep 1;332(1):153-9
15301960
J Biol Chem. 1976 Sep 10;251(17):5267-71
8458
J Med Chem. 2005 Feb 24;48(4):909-12
15715460
Mol Genet Metab. 2004 Sep-Oct;83(1-2):38-46
15464418